RMD Form 4: Global General Counsel sold 100 shares at $274.36

Rhea-AI Filing Summary

ResMed insider Michael J. Rider, who serves as Global General Counsel and Secretary, reported a sale of 100 shares of ResMed common stock at a price of $274.36 per share on 10/01/2025. The sale was executed under a Rule 10b5-1 plan adopted on 02/28/2025. Following the reported transaction, Mr. Rider beneficially owns 11,327 shares, held directly. The Form 4 is signed and dated 10/02/2025.

Insider Trade Summary

Net Seller: 100 shares ($27,436)

Net Sell 1 txn

Insider Rider Michael J

Role Global General Counsel

Sold 100 shs ($27K)

Type	Security	Shares	Price	Value
Sale	ResMed Common Stock	100	$274.36	$27K

Holdings After Transaction: ResMed Common Stock — 11,327 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Rider Michael J

(Last) (First) (Middle)

9001 SPECTRUM CENTER BLVD

(Street)

SAN DIEGO CA 92123

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RESMED INC [ RMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Global General Counsel

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
ResMed Common Stock	10/01/2025		S(1)		100	D	$274.36	11,327	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction was conducted under a Rule 10b5-1 plan adopted February 28, 2025.

	Michael J. Rider, Global General Counsel and Secretary	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did ResMed insider Michael J. Rider report on Form 4 (RMD)?

He reported a sale of 100 shares of ResMed common stock at $274.36 per share on 10/01/2025.

Under what plan was Michael J. Rider's 10/01/2025 sale executed?

The sale was conducted under a Rule 10b5-1 plan that was adopted on 02/28/2025.

How many ResMed shares does Michael J. Rider own after the reported sale?

Following the transaction he beneficially owns 11,327 shares, held directly.

What is Michael J. Rider's role at ResMed as listed on the Form 4?

He is listed as an Officer with the title Global General Counsel and Secretary.

When was the Form 4 signed by the reporting person?

The Form 4 is signed and dated 10/02/2025.